By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


SEARCH JOBS








Company News
Resverlogix (RVX.TO) Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 12/6/2016 6:45:00 AM
Resverlogix (RVX.TO) Announces Successful Phase 1 Renal Trial Results: Clears Path For Future Phase 2 Studies 11/17/2016 8:04:45 AM
Resverlogix (RVX.TO) Announces Annual And Special Meeting Of Shareholders 10/7/2016 6:58:13 AM
Resverlogix (RVX.TO) To Host Research & Development Update Featuring Key Opinion Leaders In Cardiovascular And Renal Disease 10/4/2016 9:30:17 AM
Resverlogix (RVX.TO) Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis 9/15/2016 10:46:11 AM
Resverlogix (RVX.TO) Announces Participation In Upcoming Conferences 9/12/2016 10:31:07 AM
Resverlogix (RVX.TO) Hosts Symposium To Discuss The Role Of BET-Inhibition In Modifying Cardiovascular Risk At The European Society of Cardiology Congress In Rome, Italy 8/31/2016 12:05:35 PM
Resverlogix (RVX.TO) Hosts Symposium To Discuss The Role Of BET-Inhibition In Modifying Cardiovascular Risk At The European Society of Cardiology Congress In Rome, Italy 8/29/2016 2:10:37 PM
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016 6:47:52 AM
Resverlogix (RVX.TO) Files 2016 Year-End Disclosure Documents 7/28/2016 10:23:38 AM
12345678910...
//-->